XOMA Corp (XOMA)

7.27
NASDAQ : Health Care
Prev Close 7.41
Day Low/High 7.25 / 7.56
52 Wk Low/High 3.96 / 13.98
Avg Volume 72.70K
Exchange NASDAQ
Shares Outstanding 7.59M
Market Cap 56.21M
EPS -8.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

XOMA Announces Positive Results From Its Phase 2 Proof-Of-Concept Study Of Prolactin Inhibition

X213 shown to be safe and effective, demonstrating complete suppression of lactation in study participants

XOMA Presents Positive Data From PTH1R Monoclonal Antibody Program

Unmet medical needs in parathyroid hormone-related hypercalcemia contribute to potential partnering value of overall portfolio

XOMA Announces Four Presentations At The 2017 ENDO Meeting

Oral and Poster Presentations to Highlight Preclinical and Clinical Program Advances for Hypoglycemia and Hypercalcemia

XOMA Announces Full Repayment Of Hercules Technology Growth Capital Debt Obligation

Company extinguishes Hercules term loan; repayment further reduces operating expenses and strengthens XOMA's balance sheet, reflecting its new business strategy

XOMA Appoints Matthew Perry To Its Board Of Directors

Company outlines new strategic imperatives and value drivers

XOMA Establishes Proof-of-Concept For 358 In Congenital Hyperinsulinism And Hypoglycemia Post-Bariatric Surgery

Congenital Hyperinsulinism Phase 2 study completed and multi-dose study protocol approved in the United Kingdom; Company initiates multi-dose study in hypoglycemic Post-Bariatric Surgery patients

XOMA Reaches Analyst Target Price

XOMA Reaches Analyst Target Price

In recent trading, shares of XOMA Corp have crossed above the average analyst 12-month target price of $1.09, changing hands for $6.24/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

XOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study For XOMA 358 In Children With Congenital Hyperinsulinism

XOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study For XOMA 358 In Children With Congenital Hyperinsulinism

Company Reached Agreement with MHRA on General Trial Design for Multi-dose Testing in Children 2 Years and Older in the United Kingdom

XOMA Announces Reverse Stock Split

XOMA Announces Reverse Stock Split

XOMA Initiates XOMA 358 Proof-of-Concept Study In Patients With Hypoglycemia Post Gastric Bypass Surgery

XOMA Initiates XOMA 358 Proof-of-Concept Study In Patients With Hypoglycemia Post Gastric Bypass Surgery

Novel first-in-class antibody enters clinic for second rare hypoglycemic indication